Gene therapy and ovarian cancer: A review

Obstetrics and Gynecology

Volumn 89, Issue 1, 1997, Pages 145-155

  Barnes, Mack N ^b   Deshane, Jessy S ^b   Rosenfeld, Maryland ^b   Siegal, Gene P ^b   Curiel, David T ^a   Alvarez, Ronald D ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CLINICAL PROTOCOL; CLONING VECTOR; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOPOTENTIATION; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; TUMOR IMMUNOLOGY; TUMOR SUPPRESSOR GENE;

EID: 0031021122     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(96)00296-7     Document Type: Article

References (104)

1. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-27.
2. Crawford R, Shephard J. Management of epithelial ovarian cancer. In: Shingleton H, Fowler W, Jordan J, Lawrence W, eds. Gynecologic oncology: Current diagnosis and treatment. London: W B Saunders, 1996:203-12.
3. Mullen C, Blaese M. Gene therapy of cancer. Cancer Chemother Biol Response Modif 1994;15:176-89.
4. Douglas J, Curiel D. Targeted gene therapy. Tumor Targeting 1995;1:67-84.
5. Crystal R. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995;270:404-10.
6. Blaese M, Blankestein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, et al. Vectors in cancer therapy: How will they deliver? Cancer Gene Ther 1995;2:291-7.
7. Ali M, Lemoine N, Ring C. The use of DMA viruses as vectors for gene therapy. Gene Ther 1994;1:367-84.
8. Scholfield J, Caskey C. Non-viral approaches to gene therapy. Br Med Bull 1995;51:56-71.
9. Holt J, Arteaga C. Clinical protocols: Gene therapy for the treatment of metastatic breast cancer by in vivo injection with breast-targeted retroviral vectors expressing antisense c-fos or antisense c-myc RNA. Cancer Gene Ther 1995;2:234-5.
10. Smythe W, Kaiser L, Hwang H, Amin K, Piolewski J, Eck S, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994;57:1395-401.
11. Brody S, Jaffe H, Han S, Wersto R, Crystal R. Direct in vivo gene transfer and expression in malignant cells using adenoviral vectors. Hum Gene Ther 1994;5:437-47.
12. Deshane J, Cabrera G, Grim J, Siegal G, Pike J, Alvarez R, et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 1995;59:8-14.
13. Aoki K, Yoshida T, Sugimara T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55:3810-6.
14. Hirschowitz E, Ohwada A, Pasca W, Russi T, Crystal R. In vivo adenovirus-mediated gene transfer of the Eschrichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995;6:1055-63.
15. Elion G, Furman P, Fyfe J, DeMiranda P, Beauchamp L, Schaeffer H. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74: 5716-20.
16. Furman P, McGujirt P, Keller P, Fyfe J, Elion G. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology 1980;102:420-30.
17. Abe A, Takeo T, Emi N, Tanimoto M, Ueda R, Yee J, et al. Transduction of a drug-sensitive toxic gene into human leukemia cell lines with a novel retroviral vector. Proc Soc Exp Biol Med 1993;203:354-8.
18. Culver K, Ram Z, Walbridge S, Ishii H, Oldfield E, Blaese R. In vivo gene transfer with retroviral vector-producing cells for the treatment of experimental brain tumors. Science 1992;256:1550-2.
19. Vile R, Nelson J, Castleden S, Chong H, Hart I. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune component. Cancer Res 1994;54:6228-34.
20. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996;93: 1831-5.
21. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, et al. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995;55:90-5.
22. Shaw Y, Chang S, Chiou S, Chang W, Lai M. Partial reversion of transformed phenotype of B104 cancer cells by antisense nucleic acids. Cancer Letters 1993;69:27-32.
23. Helm C, Shrestha K, Thomas S, Shingleton H, Miller D. A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro. Gynecol Oncol 1993;49:339-43.
24. Durland R, Kessler D, Gunnell S, Duvic M, Pettitt B, Hogan M. Binding of triplex helix-forming oligonucleotides to sites in gene promoters. Biochemistry 1991;30:9246-55.
25. Ebbinghouse S, Gee J, Rodu B, Mayfield C, Sanders G, Miller D. Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest 1993;92:2433-9.
26. Mayfield C, Ebbinghouse S, Gee J, Jones D, Rodu B, Squibb M, et al. Triplex formation by the human H-ras promoter inhibits Sp1 binding and in vitro transcription. J Biol Chem 1994;269:18232-8.
27. Mayfield C, Squibb M, Miller D. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplex-forming oligonucleotides. Biochemistry 1994;33:3358-63.
28. Mukhopadhyay T, Tainsky M, Cavender A, Roth J. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991;51:1744-8.
29. Georges R, Mukhopadhyay T, Zhang Y, Yen N, Roth J. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993; 53:1743-6.
30. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong N, Helene C. Short modified antisense oligonucleotide directed against Ha-ras point mutation induces selective cleavage of the mRNA and inhibits T24 cell proliferation. EMBO J 1991;30: 1111-6.
31. Calabretta B, Sims R, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991;88:2351-5.
32. Ratajczak M, Kant J, Luger S, Hijiya N, Zhang J, Zon G, et al. In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligonucleotides. Proc Natl Acad Sci USA 1992; 89:11823-7.
33. Wickstrom E, Bacon T, Gonzalez A, Freeman D, Lyman G, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc RNA. Proc Natl Acad Sci USA 1988;85:1028-32.
34. Harel-Ballan A, Ferris D, Vinocour M, Holt J, Farrar W. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxynucleotide in human T lymphocytes. J Immunol 1988;140:2431-5.
35. McManaway M, Neckers L, Loke S, Al-Nasser A, Redner R, Shiramizu B, et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990;335: 808-11.
36. Collins J, Herman P, Schuch C, Bagby G. c-myc antisense oligonucleotides inhibit the colony-forming capacity of Colo 320 colonic carcinoma cells. J Clin Invest 1992;89:1523-7.
37. Janicek M, Sevin B, Nguyen H, Averette H. Combination antigene therapy targeting c-myc and p53 in ovarian cancer cell lines. Gynecol Oncol 1995;59:87-92.
38. Neuenschwander S, Roberts C, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor 1 receptor antisense ribonucleic acid. Endocrinology 1995;136:4298-303.
39. Resnicoff M, Abraham D, Yutanawiboonachi W, Rotman H, Kajstura J, Rubin R, et al. The insulin-like growth factor 1 receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995;55: 2463-9.
40. Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 1993;69:756-60.
41. Szczylik T, Skorski T, Nicolaides N, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253:562-5.
42. Skorski T, Nieborowska-Skorska M, Nicolaides N, Szczylik C, Iversen P, Iozzo R, et al. Suppression of Philadelphia leukemia cell proliferation in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1994;91:4504-8.
43. Kashani-Sabet M, Funato T, Florenes V, Fodstad O, Scanlon K. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994;54:900-2.
44. Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yashida E, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 1992;2:3-15.
45. Lange W, Cantin E, Finke J, Dolken G. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 1993;7:1786-94.
46. Snyder D, Wu Y, Wang J, Rossi J, Swiderski P, Kaplan B, et al. Ribozyme mediated inhibition of BCR-ABL gene expression in a Philadelphia chromosome-positive cell line. Blood 1993;82:600-5.
47. Milner B, Allan L, Eccles D, Kitchener H, Leonard R, Kelly K, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-32.
48. Porter P, Gown A, Kramp S, Coltrera M. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992; 140:145-53.
49. Yang C, Cirielli C, Capogrossi M, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55:4210-3.
50. Zhang W, Fang X, Mazur W, French B, Georges R, Roth J. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:5-13.
51. Lesoon-Wood L, Kim W, Kleinman H, Weintraub B, Mixson A. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995;6:395-405.
52. Liu T, Zhang W, Taylor D, Roth J, Goepfort H, Clayman G. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994;54:3662-7.
53. Hu G, Liu W, Hania E, Fu S, Wang T, Deisseroth A. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther 1995;2:19-32.
54. Futreal P, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
55. Murakami Y, Brothman A, Leach R, White R. Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 1995; 55:3389-94.
56. Redemann N, Holzmann B, von Ruden T, Wagner E, Schlessinger J, Ullrich A. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992;12: 491-8.
57. Ueno H, Colbert H, Escobedo J, Williams L. Inhibition of PDGF beta receptor signal transduction by coexpression of a truncated receptor. Science 1991;252:844-8.
58. Prager D, Li H, Asa S, Melmed S. Dominant-negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 1994;91:2181-5.
59. Millauer B, Shawver L, Plate K, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 1994;367:576-9.
60. Shamah S, Stiles C, Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 1993;12:1674-9.
61. Deshane J, Loechel F, Conry R, Siegal G, King C, Curiel D. Intracellular single-chain antibody directed against erbB-2 down-regulates cell surface erbB-2 and exhibits a selective antiproliferative effect in erbB-2 overexpressing cancer cell lines. Gene Ther 1994;3:332-7.
62. Beerli R, Winfried W, Hynes N. Intracellular expression of single chain antibodies reverts erbB-2 transformation. J Biol Chem 1994;269:23931-6.
63. Deshane J, Grim J, Loechel S, Siegal G, Alvarez R, King C, et al. Intracellular antibody directed against erbB-2 mediates targeted tumor cell eradication by inducing apoptosis. Cancer Gene Ther 1996;3:89-98.
64. Beerli R, Wels W, Hynes N. Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Commun 1994;204:666-72.
65. Eshhar Z, Waks T, Gross G, Schindler D. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or β subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-4.
66. Hwu P, Shafer G, Treisman J, Schindler D, Gross G, Cowherd R, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 1993;178: 361-6.
67. Hwu P, Yang J, Cowherd R, Treisman J, Shafer J, Eshhar Z, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-73.
68. Yannelli J, Hyatt C, Johnston S, Hwu P, Rosenberg S. Characterization of human tumour cell lines transduced with the cDNA encoding either tumor necrosis factor α (TNF-α) or interleukin-2 (IL-2). J Immunol Methods 1993;161:77-90.
69. Conry R, Lobuglio A, Loechel F, Moore S, Sumerel L, Barlow D, et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995;2:59-65.
70. Disis M, Smith J, Murphy A, Chen W, Cheever M. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 1994;54:1071-6.
71. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60: 397-403.
72. Asher A, Mule J, Kasid A, Restifo N, Salo J, Reichart C, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991;146:3227-34.
73. Blankenstein T, Qin Z, Uberla K, Muller W, Rosen H, Volk H, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991;173:1047-52.
74. Golumbek P, Lazenby A, Levitzky H, Jafee L, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
75. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
76. Tahara H, Lotze M. Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995;2:96-106.
77. Nabel G, Nabel E, Yang Z, Fox B, Plautz G, Gao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biological activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11.
78. Biedler J, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174-84.
79. van der Zee A, Hollema H, Suurmeijer A, Krans M, Sluiter W, Willemse P, et al. Value of p-glycoprotein, glutathione S-tranferase pi, c-erbB-2, and p53 as prognostic factors in ovarian cancer. J Clin Oncol 1995;13:70-8.
80. Chin K, Tanaka S, Darlington G, Pastan I, Gottesman M. Heatshock and arsenic increase expression of the multi-drug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6.
81. Chan H, Haddad G, Thorner P, Deboer G, Lin Y, Ondrusek N, et al. P-gycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
82. Holtzmayer T, Hilsenbeck S, Van Hoff D, Roninson I. Clinical correlates of MDK-1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinomas. J Natl Cancer Inst 1992;84:1486-91.
83. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance p-glycoprotein in breast cancer. J Natl Cancer Inst 1991;83:111-6.
84. Champlin P. Kavanagh J, Deisseroth A. Use of safety-modified retrovirus to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. Hum Gene Ther 1994;5:1507-22.
85. Endicott J, Ling V. The biochemistry of P-glycoprotein mediated drug resistance. Annu Rev Biochem 1989;58:137-71.
86. Freeman S, Abboud C, Whartenby K, Packman C, Koeplin D, Moolten F, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
87. Link C, Moorman D. Clinical protocols: A phase I trial of in vivo gene therapy with the Herpes Simplex Thymidine Kinase/ Ganciclovir system for the treatment of refractory of recurrent ovarian cancer. Cancer Gene Ther 1995;2:230-1.
88. Rosenfeld M, Wang M, Siegal G, Alvarez R, Mikheeva G, Krasnykh V, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. Clin Cancer Res 1995;1:1571-80.
89. Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, Toy S, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med 1988;319:1676-80.
90. Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
91. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
92. Porgadorm A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Immunotherapy via gene therapy: Comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, of interferon genes. J Immunother 1993;14:191-201.
93. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunotherapy. J Exp Med 1990; 172:1217-24.
94. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors on mice treated with interleukin-2 gene modified tumor cells. J Exp Med 1993;177:1127-34.
95. Vieweg J, Rosenthal F, Bannerji R, Heston W, Fair W, Gansbacher B, et al. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:1760-5.
96. Berchuck A, Lyerly H. A phase I study of autologous human interleukin 2 (IL-2) gene modified tumor cells in patients with refractory metastatic ovarian cancer. Human Gene Transfer Protocols, Office of Recombinant DNA Activities. Bethesda, Maryland: National Institutes of Health, 1995.
97. Schurs E, Raymond M, Bell J, Gros P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse MDR1 cDNA. Cancer Res 1989;49:2729-34.
98. Devault A, Gros P. Two members of the mouse MDR gene family confer multidrug resistance with overlapping but distinct drug specifities. Mol Cell Biol 1990;10:1652-63.
99. Ueda K, Cardarelli C, Gottesman M, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxrubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-8.
100. Goldstein L, Galski H, Fojo A, Willingham M, Lai S, Gadzar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
101. Pastan I, Gottesman M, Ueda K, Lovelace E, Rutherford A, Willingham M. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of p-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988;85:4486-90.
102. Hanania E, Deisseroth A. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in mouse gene therapy model. Cancer Gene Ther 1994;1: 21-5.
103. Sorrentino B, Brandt S, Bodine D, Gottesman M, Pastan I, Cline A, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;257:99-103.
104. Zhang Y, Yu D, Xia W, Hung M. HER-2/neu targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 1995;10:1947-54.